Peptide Atlas · Peptide

Lixisenatide

Lixisenatide is a GLP-1 receptor agonist; in the ELIXA trial of 6,068 people with type 2 diabetes and a recent acute coronary event, it neither raised nor lowered major cardiovascular events against placebo over a median 25 months.

established

provisional
PubChem 90472060
2 citations
0 discussions
0 followers
AVE0010
Adlyxin
Lyxumia
ZP10

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Lixisenatide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Lixisenatide slowed motor disability progression over 12 months in early Parkinson's disease (phase 2)	emerging	pmid 38598572
Lixisenatide was cardiovascularly neutral after acute coronary syndrome in type 2 diabetes (ELIXA)	established	pmid 26630143

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.